You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorothiazide
Accession NumberDB00880  (APRD00721)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Structure
Thumb
Synonyms
6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Chlorothiazid
Chlorothiazide
Chlorothiazidum
Chlorthiazide
Clorotiazida
Mechlozid
Uroflux
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorothiazide Sodiuminjection500 mg/1intravenousAkorn, Inc.2012-08-13Not applicableUs
Diurilsuspension250 mg/5mLoralSalix Pharmaceuticals, Inc.1962-02-15Not applicableUs
Sodium Diurilinjection.5 mg/18mLintravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1958-10-03Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorothiazidetablet250 mg/1oralGolden State Medical Supply, Inc.2005-08-30Not applicableUs
Chlorothiazidetablet250 mg/1oralWest ward Pharmaceutical Corp2005-08-30Not applicableUs
Chlorothiazidetablet250 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Chlorothiazidetablet500 mg/1oralGolden State Medical Supply, Inc.2005-08-30Not applicableUs
Chlorothiazidetablet500 mg/1oralWest ward Pharmaceutical Corp2005-08-30Not applicableUs
Chlorothiazideinjection, powder, lyophilized, for solution500 mg/18mLintravenousFresenius Kabi USA, LLC2009-10-21Not applicableUs
Chlorothiazidetablet250 mg/1oralMylan Pharmaceuticals Inc.1975-06-26Not applicableUs
Chlorothiazidetablet500 mg/1oralMylan Pharmaceuticals Inc.1975-07-17Not applicableUs
Chlorothiazide Sodiuminjection, powder, lyophilized, for solution500 mg/18mLintravenousAmerican Regent, Inc.2015-04-01Not applicableUs
Chlorothiazide Sodiuminjection, powder, lyophilized, for solution500 mg/18mLintravenousSagent Pharmaceuticals2015-10-12Not applicableUs
Chlorothiazide Sodiuminjection, powder, lyophilized, for solution500 mg/18mLintravenousSun Pharma Global FZE2011-08-05Not applicableUs
Chlorothiazide Sodiuminjection, powder, lyophilized, for solution500 mg/18mLintravenousMylan Institutional LLC2014-08-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Supres 150 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Supres 250 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Chlorothiazide Sodium
ThumbNot applicableDBSALT000926
Categories
UNII77W477J15H
CAS number58-94-6
WeightAverage: 295.723
Monoisotopic: 294.948824782
Chemical FormulaC7H6ClN3O4S2
InChI KeyInChIKey=JBMKAUGHUNFTOL-UHFFFAOYSA-N
InChI
InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Amidine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationChlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
PharmacodynamicsLike other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Mechanism of actionAs a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingApproximately 40% bound to plasma proteins.
Metabolism

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney.

Route of eliminationChlorothiazide is not metabolized but is eliminated rapidly by the kidney. After oral doses, 10 to 15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Half life45-120 minutes
ClearanceNot Available
ToxicityOral, rat LD50: > 10 g/kg. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Chlorothiazide Action PathwayDrug actionSMP00078
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9119
Blood Brain Barrier-0.9506
Caco-2 permeable-0.7368
P-glycoprotein substrateNon-substrate0.706
P-glycoprotein inhibitor INon-inhibitor0.8482
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.755
CYP450 2D6 substrateNon-substrate0.8379
CYP450 3A4 substrateNon-substrate0.6308
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9382
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8658
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7792
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.5023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9654
hERG inhibition (predictor II)Non-inhibitor0.9352
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Salix pharmaceuticals inc
  • Abc holding corp
  • Lederle laboratories div american cyanamid co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Lundbeck inc
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral250 mg/1
Tabletoral500 mg/1
Injectionintravenous500 mg/1
Injection, powder, lyophilized, for solutionintravenous500 mg/18mL
Suspensionoral250 mg/5mL
Injectionintravenous.5 mg/18mL
Tabletoral
Prices
Unit descriptionCostUnit
Diuril sodium 500 mg vial519.62USD vial
Chlorothiazide sod 500 mg vial357.24USD vial
Microzide 12.5 mg capsule0.95USD capsule
Aldoclor 250-250 mg tablet0.67USD tablet
Chlorothiazide 500 mg tablet0.36USD tablet
Chlorothiazide 250 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point342.5-343Novello, F.C.; US. Patent 2,809,194; October 8,1957; assigned to Merck & Co.,Inc. Hinkley, D.F.; US. Patent 2,937,169; May 17,1960; assigned to Merck & Co., Inc.
water solubility266 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.24HANSCH,C ET AL. (1995)
logS-3.05ADME Research, USCD
Caco2 permeability-6.72ADME Research, USCD
pKa6.85MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.398 mg/mLALOGPS
logP0.41ALOGPS
logP-0.44ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)1.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity62.51 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Eugene S. Barabas, “Water soluble complex of a poly (vinyl lactam) and chlorothiazide and process for producing same.” U.S. Patent US4713238, issued December, 1985.

US4713238
General ReferencesNot Available
External Links
ATC CodesC03AA04C03AB04C03AH01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Chlorothiazide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Chlorothiazide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorothiazide.
AcebutololChlorothiazide may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Chlorothiazide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Chlorothiazide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Chlorothiazide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.
AldosteroneAldosterone may increase the hypokalemic activities of Chlorothiazide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorothiazide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Chlorothiazide.
AliskirenChlorothiazide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorothiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorothiazide.
AlprenololAlprenolol may increase the hypotensive activities of Chlorothiazide.
AmbrisentanChlorothiazide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Chlorothiazide.
AmifostineChlorothiazide may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Chlorothiazide.
AmlodipineAmlodipine may increase the hypotensive activities of Chlorothiazide.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
AmoxapineAmoxapine may increase the hyponatremic activities of Chlorothiazide.
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amyl Nitrite.
Anisotropine MethylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Chlorothiazide.
ArformoterolArformoterol may increase the hypokalemic activities of Chlorothiazide.
AripiprazoleAripiprazole may increase the hypotensive activities of Chlorothiazide.
AtenololAtenolol may increase the hypotensive activities of Chlorothiazide.
Atracurium besylateThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Chlorothiazide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.
BalsalazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Chlorothiazide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.
BenactyzineThe serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Chlorothiazide.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Chlorothiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Chlorothiazide.
BenoxaprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine.
BepridilChlorothiazide may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Chlorothiazide.
BetaxololBetaxolol may increase the hypotensive activities of Chlorothiazide.
BethanidineBethanidine may increase the hypotensive activities of Chlorothiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide.
BimatoprostChlorothiazide may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Chlorothiazide.
BosentanBosentan may increase the hypotensive activities of Chlorothiazide.
BretyliumChlorothiazide may increase the hypotensive activities of Bretylium.
BrimonidineChlorothiazide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Chlorothiazide.
BromfenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Chlorothiazide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Chlorothiazide.
BumetanideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.
BupranololChlorothiazide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Chlorothiazide.
CandesartanCandesartan may increase the hypotensive activities of Chlorothiazide.
CandoxatrilCandoxatril may increase the hypotensive activities of Chlorothiazide.
CaptoprilChlorothiazide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorothiazide.
CaroxazoneCaroxazone may increase the hypotensive activities of Chlorothiazide.
CarprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Chlorothiazide.
CarvedilolChlorothiazide may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Chlorothiazide.
CelecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.
CeliprololChlorothiazide may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.
ChlorphenoxamineThe serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Chlorothiazide.
CholestyramineCholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Chlorothiazide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.
CilazaprilChlorothiazide may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Chlorothiazide.
ClenbuterolClenbuterol may increase the hypokalemic activities of Chlorothiazide.
ClevidipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Chlorothiazide.
ClocortoloneClocortolone may increase the hypokalemic activities of Chlorothiazide.
ClomipramineClomipramine may increase the hyponatremic activities of Chlorothiazide.
ClonidineClonidine may increase the hypotensive activities of Chlorothiazide.
ClonixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide.
ColesevelamColesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Chlorothiazide.
CryptenamineCryptenamine may increase the hypotensive activities of Chlorothiazide.
CyclopentolateThe serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.
CyclothiazideCyclothiazide may increase the hypotensive activities of Chlorothiazide.
D-LimoneneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with D-Limonene.
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Chlorothiazide.
DarifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.
DebrisoquinChlorothiazide may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Chlorothiazide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorothiazide.
DeserpidineChlorothiazide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.
DesloratadineThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Chlorothiazide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Chlorothiazide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Chlorothiazide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Chlorothiazide.
DexetimideThe serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorothiazide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorothiazide.
DiazoxideDiazoxide may increase the hypotensive activities of Chlorothiazide.
DiazoxideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide.
DicyclomineThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Chlorothiazide.
DiflunisalThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Chlorothiazide.
DifluprednateDifluprednate may increase the hypokalemic activities of Chlorothiazide.
DigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.
DiltiazemDiltiazem may increase the hypotensive activities of Chlorothiazide.
DinutuximabThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.
DipivefrinDipivefrin may increase the hypokalemic activities of Chlorothiazide.
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Chlorothiazide.
DofetilideChlorothiazide may increase the QTc-prolonging activities of Dofetilide.
DorzolamideDorzolamide may increase the hypotensive activities of Chlorothiazide.
DoxazosinDoxazosin may increase the hypotensive activities of Chlorothiazide.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide.
DroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Chlorothiazide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.
DuloxetineChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineChlorothiazide may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorothiazide.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorothiazide.
EnalaprilEnalapril may increase the hypotensive activities of Chlorothiazide.
EnalaprilatChlorothiazide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Chlorothiazide.
EpinephrineEpinephrine may increase the hypokalemic activities of Chlorothiazide.
EpirizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide.
EpoprostenolChlorothiazide may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Chlorothiazide.
EquileninEquilenin may increase the hypokalemic activities of Chlorothiazide.
EquilinEquilin may increase the hypokalemic activities of Chlorothiazide.
EscitalopramEscitalopram may increase the hyponatremic activities of Chlorothiazide.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.
EstroneEstrone may increase the hypokalemic activities of Chlorothiazide.
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Chlorothiazide.
EthopropazineThe serum concentration of Chlorothiazide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.
EtodolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Chlorothiazide.
EtoricoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide.
Evening primrose oilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorothiazide.
exisulindThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with exisulind.
FelodipineChlorothiazide may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Chlorothiazide.
FenoldopamFenoldopam may increase the hypotensive activities of Chlorothiazide.
FenoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Chlorothiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.
FesoterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Chlorothiazide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Chlorothiazide.
FlunisolideFlunisolide may increase the hypokalemic activities of Chlorothiazide.
FlunixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.
FluocinonideFluocinonide may increase the hypokalemic activities of Chlorothiazide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Chlorothiazide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Chlorothiazide.
FluoxetineFluoxetine may increase the hyponatremic activities of Chlorothiazide.
FluprednideneFluprednidene may increase the hypokalemic activities of Chlorothiazide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Chlorothiazide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Chlorothiazide.
FlurbiprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Chlorothiazide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Chlorothiazide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Chlorothiazide.
FormoterolFormoterol may increase the hypokalemic activities of Chlorothiazide.
FosinoprilFosinopril may increase the hypotensive activities of Chlorothiazide.
FurazolidoneFurazolidone may increase the hypotensive activities of Chlorothiazide.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.
Gallamine TriethiodideThe serum concentration of Chlorothiazide can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorothiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide.
GlycopyrroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Chlorothiazide.
GuanadrelGuanadrel may increase the hypotensive activities of Chlorothiazide.
GuanethidineChlorothiazide may increase the hypotensive activities of Guanethidine.
GuanfacineChlorothiazide may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorothiazide.
HexamethoniumChlorothiazide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
HMPL-004The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Chlorothiazide.
HydralazineChlorothiazide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideChlorothiazide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Chlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Chlorothiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.
HyoscyamineThe serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Chlorothiazide.
IndacaterolIndacaterol may increase the hypokalemic activities of Chlorothiazide.
IndalpineIndalpine may increase the hyponatremic activities of Chlorothiazide.
IndapamideIndapamide may increase the hypotensive activities of Chlorothiazide.
IndenololChlorothiazide may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen.
IndoraminChlorothiazide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorothiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorothiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.
Ipratropium bromideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Chlorothiazide.
IproniazidIproniazid may increase the hypotensive activities of Chlorothiazide.
IrbesartanChlorothiazide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Chlorothiazide.
IsoetarineIsoetarine may increase the hypokalemic activities of Chlorothiazide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Chlorothiazide.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Chlorothiazide.
IvabradineChlorothiazide may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.
KetoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Chlorothiazide.
LacidipineChlorothiazide may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Chlorothiazide.
LeflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Chlorothiazide.
LevobunololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol.
LevodopaChlorothiazide may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Chlorothiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.
LicoriceLicorice may increase the hypokalemic activities of Chlorothiazide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorothiazide.
LisinoprilLisinopril may increase the hypotensive activities of Chlorothiazide.
LithiumChlorothiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorothiazide.
LofexidineChlorothiazide may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Chlorothiazide.
LoxoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Chlorothiazide.
LumiracoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib.
MacitentanChlorothiazide may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.
ManidipineChlorothiazide may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.
MasoprocolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Chlorothiazide.
MecamylamineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Chlorothiazide.
Meclofenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Chlorothiazide.
Mefenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Chlorothiazide.
MeloxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorothiazide.
MethanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorothiazide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Chlorothiazide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.
MethyldopaChlorothiazide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Chlorothiazide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Chlorothiazide.
MetipranololChlorothiazide may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Chlorothiazide can be increased when it is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Chlorothiazide.
MetoprololMetoprolol may increase the hypotensive activities of Chlorothiazide.
MibefradilChlorothiazide may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorothiazide.
MilnacipranMilnacipran may increase the hyponatremic activities of Chlorothiazide.
MinaprineMinaprine may increase the hypotensive activities of Chlorothiazide.
MinoxidilMinoxidil may increase the hypotensive activities of Chlorothiazide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorothiazide.
MoclobemideMoclobemide may increase the hypotensive activities of Chlorothiazide.
MoexiprilMoexipril may increase the hypotensive activities of Chlorothiazide.
MolsidomineMolsidomine may increase the hypotensive activities of Chlorothiazide.
MometasoneMometasone may increase the hypokalemic activities of Chlorothiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.
MoxonidineChlorothiazide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Chlorothiazide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.
NadololChlorothiazide may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.
NaproxenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorothiazide.
NCX 4016The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with NCX 4016.
NebivololChlorothiazide may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Chlorothiazide.
NicardipineNicardipine may increase the hypotensive activities of Chlorothiazide.
NicorandilNicorandil may increase the hypotensive activities of Chlorothiazide.
NifedipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.
NiguldipineChlorothiazide may increase the hypotensive activities of Niguldipine.
NilvadipineChlorothiazide may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Chlorothiazide.
NisoldipineNisoldipine may increase the hypotensive activities of Chlorothiazide.
NitrendipineChlorothiazide may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide.
NitroprussideNitroprusside may increase the hypotensive activities of Chlorothiazide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Chlorothiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorothiazide.
NVA237The serum concentration of Chlorothiazide can be increased when it is combined with NVA237.
ObinutuzumabChlorothiazide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Chlorothiazide.
OlanzapineOlanzapine may increase the hyponatremic activities of Chlorothiazide.
OlmesartanOlmesartan may increase the hypotensive activities of Chlorothiazide.
OlodaterolOlodaterol may increase the hypokalemic activities of Chlorothiazide.
OlopatadineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.
OmapatrilatChlorothiazide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorothiazide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Chlorothiazide.
OrgoteinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oxcarbazepine.
OxprenololChlorothiazide may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.
OxyphenbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Chlorothiazide can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Chlorothiazide.
ParecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.
PargylineChlorothiazide may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Chlorothiazide.
PenbutololChlorothiazide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
PentoliniumChlorothiazide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Chlorothiazide.
PerindoprilPerindopril may increase the hypotensive activities of Chlorothiazide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.
PhenelzinePhenelzine may increase the hypotensive activities of Chlorothiazide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorothiazide.
PheniprazinePheniprazine may increase the hypotensive activities of Chlorothiazide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
PhenoxybenzamineChlorothiazide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Chlorothiazide.
PhentolaminePhentolamine may increase the hypotensive activities of Chlorothiazide.
PhenylbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Chlorothiazide.
PimecrolimusThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.
PinacidilChlorothiazide may increase the hypotensive activities of Pinacidil.
PindololChlorothiazide may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.
PipecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Chlorothiazide.
PirenzepineThe serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Chlorothiazide.
PiroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Chlorothiazide.
PolythiazideChlorothiazide may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide.
PrazosinPrazosin may increase the hypotensive activities of Chlorothiazide.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Chlorothiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Chlorothiazide.
PrednisonePrednisone may increase the hypokalemic activities of Chlorothiazide.
PregnenolonePregnenolone may increase the hypokalemic activities of Chlorothiazide.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Chlorothiazide.
ProcaterolProcaterol may increase the hypokalemic activities of Chlorothiazide.
ProcyclidineThe serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Propantheline.
PropranololPropranolol may increase the hypotensive activities of Chlorothiazide.
PTC299The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.
QuinaprilChlorothiazide may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Chlorothiazide.
RamiprilRamipril may increase the hypotensive activities of Chlorothiazide.
RasagilineRasagiline may increase the hypotensive activities of Chlorothiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.
RemikirenRemikiren may increase the hypotensive activities of Chlorothiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide.
RescinnamineChlorothiazide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Chlorothiazide.
ResveratrolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Chlorothiazide.
RiociguatChlorothiazide may increase the hypotensive activities of Riociguat.
RisperidoneChlorothiazide may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Chlorothiazide.
RituximabChlorothiazide may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide.
SafrazineSafrazine may increase the hypotensive activities of Chlorothiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Chlorothiazide.
SalicylamideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Chlorothiazide.
SalsalateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.
SaprisartanChlorothiazide may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorothiazide.
ScopolamineThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
SelegilineSelegiline may increase the hypotensive activities of Chlorothiazide.
SelexipagChlorothiazide may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Chlorothiazide.
SildenafilSildenafil may increase the antihypertensive activities of Chlorothiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide.
SitaxentanChlorothiazide may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.
SpiraprilChlorothiazide may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.
SRT501The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.
SulfasalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.
SulpirideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Chlorothiazide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide.
TelmisartanChlorothiazide may increase the hypotensive activities of Telmisartan.
TemocaprilChlorothiazide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Chlorothiazide.
TeriflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.
TerlipressinChlorothiazide may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Chlorothiazide.
Tiaprofenic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.
TiboloneChlorothiazide may increase the hypotensive activities of Tibolone.
TicrynafenChlorothiazide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Chlorothiazide.
TiotropiumThe serum concentration of Chlorothiazide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Chlorothiazide.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.
TolazolineTolazoline may increase the hypotensive activities of Chlorothiazide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.
Tolfenamic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Chlorothiazide.
TolterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine.
TopiramateChlorothiazide may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Chlorothiazide.
ToremifeneChlorothiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.
TrandolaprilTrandolapril may increase the hypotensive activities of Chlorothiazide.
TranilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Chlorothiazide.
TravoprostTravoprost may increase the hypotensive activities of Chlorothiazide.
TrazodoneTrazodone may increase the hyponatremic activities of Chlorothiazide.
TreprostinilTreprostinil may increase the hypotensive activities of Chlorothiazide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Chlorothiazide.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.
TrichlormethiazideChlorothiazide may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl.
TrimazosinChlorothiazide may increase the hypotensive activities of Trimazosin.
TrimethaphanChlorothiazide may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorothiazide.
TropicamideThe serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Chlorothiazide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Chlorothiazide.
UmeclidiniumThe serum concentration of Chlorothiazide can be increased when it is combined with Umeclidinium.
UnoprostoneChlorothiazide may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Chlorothiazide.
VardenafilVardenafil may increase the antihypertensive activities of Chlorothiazide.
VecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.
VilanterolVilanterol may increase the hypokalemic activities of Chlorothiazide.
VilazodoneVilazodone may increase the hyponatremic activities of Chlorothiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorothiazide.
VortioxetineVortioxetine may increase the hyponatremic activities of Chlorothiazide.
XylometazolineChlorothiazide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Chlorothiazide.
ZaltoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Chlorothiazide.
ZomepiracThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Thakker RV: Molecular pathology of renal chloride channels in Dent's disease and Bartter's syndrome. Exp Nephrol. 2000 Nov-Dec;8(6):351-60. [PubMed:11014932 ]
  2. Schmidt H, Kabesch M, Schwarz HP, Kiess W: Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res. 2001 Jun;33(6):354-7. [PubMed:11456284 ]
  3. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):680-4. Epub 2003 Jan 6. [PubMed:12515852 ]
  4. Maki N, Komatsuda A, Wakui H, Ohtani H, Kigawa A, Aiba N, Hamai K, Motegi M, Yamaguchi A, Imai H, Sawada K: Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome. Nephrol Dial Transplant. 2004 Jul;19(7):1761-6. Epub 2004 Apr 6. [PubMed:15069170 ]
  5. Reinalter SC, Jeck N, Peters M, Seyberth HW: Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand. 2004 Aug;181(4):513-21. [PubMed:15283765 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8. [PubMed:14656370 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]
  3. Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney. Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8. [PubMed:12388412 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23